Mankind Pharma Limited share price

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, urology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory, and other diseases. It also provides consumer healthcare products, such as condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading of pharmaceutical and health care …Read more

Website NSE हिंदी में BSE

HealthcareDrug Manufacturers - Specialty & GenericNifty 500 Nifty Midcap 150NSE: MANKINDISIN INE634S01028

16 Oct 2026, 3:29 PM IST₹2,275.50▼ 72.10 (3.07%)

Market Cap₹ 93,988 Cr.
Current Price₹ 2,275.50
High / Low₹ 2,642 / 1,910
Stock P/E46.0
Book Value₹ 395
Dividend Yield0.00 %
ROCE13.7 %
ROE12.50 %
Face Value₹ 1.0

More figures (10)

EPS (TTM)₹ 49.42
Price / Book5.76
OPM19.9 %
Debt / Equity0.39
Sales growth (3Y)17.7 %
Profit growth (3Y)14.0 %
Promoter holding75.4 %
EV / EBITDA25.3
Beta0.45
All-time high₹ 3,055

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
MANKIND	+1.31%	-10.62%	+8.13%	+3.60%	-7.32%	+7.84%	—
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

Mankind Pharma Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹93,988 crore.
It trades at 46.0 times its last 12 months' earnings and 5.8 times book value.
Revenue grew 17.7% a year over the last 3 years, profit 14.0% a year.
Return on equity was 12.5% and return on capital employed 13.7% in the latest year.
Debt was 0.39 times shareholders' equity.
The share price is 13.9% below its 52-week high and down 7.3% over one year.
Promoters and insiders hold about 75.4%; institutions about 18.7%.

Pros

Sales have grown 17.7% a year over the last 3 years.
Latest quarter (Jun 2026): sales up 13% and profit up 29% from a year ago.
Healthy return on equity of 17.4% on average over the last 3 years.
Borrowings are moderate at 0.39 times shareholders' equity.
Institutional (FII + DII) holding has risen by 8.4 points over 3 years.

Cons

Promoter holding has fallen by 3.88 points over 3 years, to 72.62%.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About Mankind Pharma Limited

Employees: 20,451
Head office: New Delhi
NSE industry: Healthcare

HealthcareHealthcareDrug Manufacturers - Specialty & Generic

Part ofNifty 500 Nifty Midcap 150

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	Mankind Pharma	2,275.50	46.0	93,988	0.00	574	29.12	4,031	12.89	13.7	12.5	5.76	19.9	0.39	75.39	14,278	17.7
2.	Sun Pharmaceutical Industries	1,758.80	34.9	4,21,995	0.91	2,895	34.65	15,184	18.48	17.9	14.7	5.05	23.4	0.06	55.61	58,220	10.4
3.	Divi's Laboratories	9,144.50	83.0	2,42,758	0.33	902	36.25	3,080	19.15	19.0	16.2	14.48	28.4	0.00	52.00	10,476	11.0
4.	Torrent Pharmaceuticals	4,558.90	72.8	1,73,406	0.83	566	3.28	4,921	54.85	9.1	27.1	18.39	25.0	1.79	63.18	13,980	13.3
5.	Zydus Lifesciences	1,123.00	25.0	1,12,020	0.09	940	-19.74	7,802	24.03	19.0	19.7	4.17	21.7	0.46	75.18	26,720	16.5
6.	Laurus Labs	2,060.10	101.8	1,11,310	0.12	362	123.94	2,026	29.10	19.5	18.2	20.98	19.4	0.48	32.03	6,813	3.8
7.	Cipla	1,325.10	31.8	1,07,051	0.98	789	-35.42	7,077	7.26	14.9	11.8	3.11	17.5	0.02	31.13	27,712	7.2
8.	Dr. Reddy's Laboratories	1,233.00	31.0	1,02,707	0.66	444	-68.72	8,071	-5.56	14.2	12.1	2.68	14.9	0.21	30.14	33,593	11.0
9.	Aurobindo Pharma	1,666.90	26.0	95,910	0.00	1,033	14.29	9,106	8.65	13.5	9.9	2.56	15.6	0.21	54.79	33,385	10.7
10.	Lupin	1,961.60	16.2	89,702	0.91	1,415	83.17	8,217	47.73	28.3	26.9	3.99	24.8	0.29	47.02	27,488	19.1
	Median: 47 Co.	1,860.20	31.4	17,624	0.33	846	21.70	7,440	18.81	16.4	14.1	4.17	16.1	0.25	53.40	27,104	13.3

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Consolidated figures in ₹ crore /

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	2,579	2,708	2,607	2,441	2,893	3,077	3,230	3,079	3,570	3,697	3,567	3,443	4,031
YOY Sales Growth %				18.92%	12.21%	13.60%	23.90%	26.15%	23.40%	20.17%	10.44%	11.81%	12.89%
	1,924	2,025	2,000	1,850	2,212	2,226	2,400	2,396	2,724	2,776	2,648	2,513	2,974
Material Cost %	32%	30%	32%	30%	28%	28%	29%	28%	30%	29%	27%	28%	27%
Employee Cost %	21%	21%	22%	24%	22%	21%	22%	23%	22%	22%	23%	22%	23%
Other Expenses %	21%	23%	23%	22%	26%	23%	23%	26%	25%	24%	24%	23%	24%
Operating Profit	655	683	607	591	682	850	830	683	847	921	919	930	1,056
OPM %	25%	25%	23%	24%	24%	28%	26%	22%	24%	25%	26%	27%	26%
	59	60	70	92	101	109	77	251	80	92	73	114	45
Exceptional items											-107	-23
Interest	6	9	9	9	11	7	221	191	171	170	157	142	110
Depreciation	87	96	110	105	108	106	192	231	219	222	223	223	226
Profit before tax	620	638	558	569	664	847	494	513	537	622	506	656	766
	21%	20%	18%	17%	19%	22%	23%	17%	18%	17%	19%	15%	26%
Current tax	145	162	71	115	139	168	158	132	111	125	154	193	211
Deferred tax	-14	-32	31	-20	-14	22	-45	-45	-15	-21	-59	-93	-15
	494	511	460	477	543	659	385	425	445	520	414	559	574
Profit from associates	5	3	5	2	4	3	3	2	3	2	3	3	4
Minority share		10	6	5	7	5	4	4	6	9	5	5
Profit to shareholders		501	454	471	536	653	380	425	438	512	409	554
YOY Profit Growth %				62.27%	9.89%	28.89%	-16.37%	-10.90%	-18.13%	-21.05%	7.64%	31.74%	29.12%
EPS in Rs	12.15	12.51	11.33	11.76	13.39	16.31	9.45	10.19	10.62	12.39	9.90	13.44	13.76
Raw filing

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	2,300	2,453	2,359	2,153	2,403	2,530	2,397	2,127	2,541	2,609	2,633	2,582	2,964
YOY Sales Growth %				14.99%	4.48%	3.11%	1.61%	-1.21%	5.75%	3.12%	9.85%	21.41%	16.63%
	1,761	1,818	1,755	1,605	1,831	1,778	1,656	1,650	1,868	1,916	1,854	1,663	2,035
Material Cost %	34%	31%	31%	29%	29%	28%	28%	26%	26%	27%	25%	22%	25%
Employee Cost %	21%	20%	21%	24%	22%	21%	22%	25%	23%	23%	23%	21%	23%
Other Expenses %	21%	22%	23%	22%	26%	22%	20%	26%	24%	23%	22%	21%	21%
Operating Profit	539	635	603	547	572	752	741	477	673	693	778	919	929
OPM %	23%	26%	26%	25%	24%	30%	31%	22%	26%	27%	30%	36%	31%
	57	58	67	84	95	106	70	219	64	78	57	127	34
Exceptional items											-83	-23
Interest	2	4	4	4	6	2	199	162	147	147	138	125	95
Depreciation	69	77	90	82	83	85	87	105	97	99	108	109	111
Profit before tax	526	612	576	545	577	770	524	429	494	525	505	788	757
	22%	23%	15%	17%	16%	22%	21%	11%	16%	13%	11%	9%	26%
Current tax	109	122	74	111	108	131	135	93	92	98	122	162	165
Deferred tax	8	17	15	-20	-15	37	-28	-47	-11	-32	-66	-88	33
	409	473	487	454	513	634	416	382	413	459	449	714	558
YOY Profit Growth %				61.63%	25.46%	34.16%	-14.51%	-15.79%	-19.62%	-27.67%	7.95%	86.58%	35.31%
EPS in Rs	10.22	11.80	12.16	11.34	12.82	15.84	10.35	18.54	10.00	11.12	10.89	17.29	13.53
Raw filing

Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Consolidated figures in ₹ crore /

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	8,749	10,335	12,207	14,278	14,738
YOY Sales Growth %		18.12%	18.12%	16.96%
	6,849	7,800	9,190	10,660	10,911
Material Cost %	33%	31%	29%	28%	28%
Employee Cost %	22%	22%	22%	22%	22%
Other Expenses %	23%	22%	25%	24%	24%
Operating Profit	1,901	2,535	3,018	3,617	3,827
OPM %	22%	25%	25%	25%	26%
	129	281	537	359	324
Exceptional items				-130	-130
Interest	44	34	429	639	579
Depreciation	326	398	621	886	893
Profit before tax	1,659	2,384	2,504	2,321	2,549
	22%	19%	20%	17%	19%
Current tax	328	493	596	583
Deferred tax	34	-35	-86	-188
	1,310	1,942	2,011	1,938	2,068
Profit from associates	12	15	12	12	12
Minority share	28	29	20	25	19
Profit to shareholders	1,282	1,913	1,986	1,913
YOY Profit Growth %		48.26%	3.57%	-3.63%
EPS in Rs	32.00	47.75	49.28	46.35	49.49
Dividend Payout %				2%

Compounded Sales Growth

3 Years:: 18%
TTM:: 14%

Compounded Profit Growth

3 Years:: 14%
TTM:: 8%

Stock Price CAGR

3 Years:: 8%
1 Year:: -7%

Return on Equity

4 Years:: 17%
Last Year:: 13%

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	8,127	9,265	9,498	10,421	10,787
YOY Sales Growth %		14.00%	2.51%	9.72%
	6,430	6,940	6,935	7,335	7,468
Material Cost %	35%	31%	27%	25%	25%
Employee Cost %	21%	21%	22%	23%	23%
Other Expenses %	23%	22%	23%	22%	22%
Operating Profit	1,697	2,325	2,563	3,086	3,319
OPM %	21%	25%	27%	30%	31%
	163	267	493	326	295
Exceptional items				-106	-106
Interest	28	15	372	562	506
Depreciation	270	318	378	429	427
Profit before tax	1,563	2,260	2,306	2,315	2,575
	20%	19%	18%	12%	15%
Current tax	292	417	470	473
Deferred tax	23	20	-48	-196
	1,248	1,823	1,945	2,038	2,180
YOY Profit Growth %		46.08%	6.69%	4.73%
EPS in Rs	31.16	45.52	94.80	49.37	52.83
Dividend Payout %				2%

Compounded Sales Growth

3 Years:: 9%
TTM:: 12%

Compounded Profit Growth

3 Years:: 18%
TTM:: 18%

Stock Price CAGR

3 Years:: 8%
1 Year:: -7%

Return on Equity

4 Years:: 17%
Last Year:: 13%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	40	40	41	41
Reserves	7,395	9,323	14,291	16,259
	170	207	8,511	6,312
Long term borrowings	23	25	5,526	2,821
Short term borrowings	139	171	2,957	3,383
	2,110	2,393	4,916	5,468
Trade payables	1,008	777	1,133	1,341
Minority interest	188	213	236	261
Current liabilities	1,863	2,120	5,664	6,507
Total Liabilities	9,715	11,963	27,760	28,080
	3,076	3,171	3,259	3,714
Gross block	3,820	4,134	4,424	5,129
Accumulated depreciation	744	963	1,165	1,415
Goodwill & intangibles	1,778	1,683	16,616	16,134
CWIP	552	239	351	754
	6,088	8,553	24,149	23,611
Inventories	1,498	1,553	2,094	2,144
Trade receivables	576	848	1,538	1,730
Cash & equivalents	305	382	407	392
Current assets	4,328	6,568	6,988	6,954
Total Assets	9,715	11,963	27,760	28,080

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	1,813	2,152	2,413	3,121
Profit for the year	1,282	1,913	1,991	1,913
Working capital changes	167	-18	-146	105
Direct taxes paid	-323	-442	-567	-593
	-1,054	-2,082	-12,683	-196
Fixed assets purchased	-832	-389	-531	-737
Fixed assets sold	6	8	12	3
Investments purchased	-898	-2,291	-5,492	-4,746
Investments sold	712	545	6,388	5,218
	-740	5	10,233	-2,953
Proceeds from borrowings	1,099	401	12,451	3,978
Repayment of borrowings	-1,794	-367	-5,073	-6,218
Interest paid	-42	-26	-98	-669
Dividends paid				-41
Net Cash Flow	19	76	-37	-28
Free Cash Flow	981	1,763	1,883	2,384

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	17.2%	22.8%	16.8%	12.5%
ROCE	21.8%	24.6%	13.3%	13.7%
Operating margin	18.8%	21.8%	20.6%	19.9%
Net margin	14.7%	18.6%	16.3%	13.4%
Debt / equity	0.02	0.02	0.59	0.39
Current ratio	2.32	3.10	1.23	1.07
Debtor days	24	30	46	44
Inventory days	185	174	214	189
Days payable	124	87	116	118
Cash conversion cycle	85	117	144	115
Working capital days	103	158	40	11

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 72.62%
FIIs 9.37%
DIIs 15.56%
Public 2.45%

%	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	76.50%	74.88%	74.87%	74.87%	72.71%	72.70%	72.68%	72.67%	72.66%	72.66%	72.63%	72.62%
	6.74%	9.87%	11.58%	12.37%	13.34%	12.92%	13.07%	12.84%	11.34%	10.24%	9.45%	9.37%
Foreign portfolio investors (Cat. I)	6.49%	9.67%	11.26%	12.02%	13.02%	12.61%	12.73%	12.44%	11.15%	10.04%	9.26%	9.18%
Foreign portfolio investors (Cat. II)	0.25%	0.20%	0.32%	0.35%	0.32%	0.31%	0.34%	0.39%	0.19%	0.20%	0.19%	0.19%
	9.79%	11.14%	9.95%	9.90%	11.06%	11.48%	11.50%	11.92%	13.25%	14.46%	15.39%	15.56%
Mutual funds	7.55%	8.57%	7.37%	6.99%	7.83%	7.67%	7.34%	7.78%	9.30%	10.36%	10.87%	11.31%
Insurance companies	1.94%	2.17%	2.14%	2.34%	2.21%	2.23%	2.24%	1.77%	1.12%	1.14%	1.54%	1.37%
Provident & pension funds				0.13%	0.52%	1.02%	1.59%	2.08%	2.61%	2.77%	2.77%	2.65%
Alternative investment funds	0.29%	0.40%	0.43%	0.45%	0.49%	0.52%	0.29%	0.24%	0.19%	0.15%	0.17%	0.17%
	6.97%	4.11%	3.61%	2.86%	2.90%	2.90%	2.75%	2.57%	2.75%	2.64%	2.53%	2.45%
Retail (up to ₹2 lakh)	1.14%	1.22%	1.46%	1.55%	1.60%	1.64%	1.47%	1.31%	1.47%	1.34%	1.29%	1.26%
HNIs (above ₹2 lakh)							0.05%	0.05%	0.05%	0.05%
NRIs	0.04%	0.05%	0.06%	0.07%	0.07%	0.07%	0.06%	0.06%	0.06%	0.06%	0.05%	0.06%
Bodies corporate	5.73%	2.78%	2.03%	1.17%	1.15%	1.11%	1.07%	1.07%	1.08%	1.07%	1.04%	1.04%
No. of Shareholders	1,27,449	1,35,116	1,53,450	1,63,854	1,71,281	1,80,597	1,79,549	1,70,347	1,77,539	1,77,606	1,66,715	1,63,770

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Mutual funds & institutions holding Mankind Pharma

Holder (above 1%)	Stake
Nps Trust- A/C Lic Pension Fund Scheme - State GovPension fund	2.65%
Nippon Life India Trustee Ltd-A/C Nippon India RetMutual fund	2.45%
SBI ESG Exclusionary Strategy FundMutual fund	1.49%
ADITYA BIRLA SUN LIFE MUTUAL FUND - ADITYA BIRLA SMutual fund · see the fund house	1.21%

As named in the shareholding pattern for Sep 2026 filed with NSE; mutual funds together hold 11.31% of the company. Shareholders below 1% are not named in the filing.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

Concalls & investor meets

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Results announced: 29 Oct 2026
Ex-dividend date: 8 Aug 2025
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about Mankind Pharma Limited

What is the share price of Mankind Pharma Limited today?

Mankind Pharma Limited (MANKIND) last traded at ₹2,275.50 on NSE (16 Oct 2026, 3:29 PM IST). Prices may be delayed.

What is the market cap of Mankind Pharma Limited?

About ₹93,988 crore at the latest price.

What is the P/E ratio of Mankind Pharma Limited?

About 46.0 times its earnings over the last 12 months.

Is Mankind Pharma Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy Mankind Pharma Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.

Mankind Pharma Limited share price

Price chart

Quick take

Pros

Cons

AI analysis

About Mankind Pharma Limited

Peer comparison

Quarterly Results

Profit & Loss

Projection — your assumptions

Related party transactions

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Mutual funds & institutions holding Mankind Pharma

Documents

Announcements

Annual reports

Credit ratings

Concalls & investor meets

Key dates

Trade with our broking desk

Latest news

In the news

From the company (NSE)

Questions about Mankind Pharma Limited

Have a question about this topic?

Book your free wealth consultation

Request received!

What happens next